International Edition
Latest News
Health

Joan Massagué: ‘Finally, We Are Curing Metastases

New cancer therapies and genetic insights are changing survival outlooks across major research centers, nationalgeographic.pt reported on Thursday. Researchers across engineering, computing, and physics laboratories are studying how primary tumors spread and colonize distant organs. Metastasis remains the…

Joan Massagué: 'Finally, We Are Curing Metastases

New cancer therapies and genetic insights are changing survival outlooks across major research centers, nationalgeographic.pt reported on Thursday.

Researchers across engineering, computing, and physics laboratories are studying how primary tumors spread and colonize distant organs.

Metastasis remains the primary driver of mortality in solid tumors, accounting for roughly 90% of deaths from the disease according to World Health Organization data cited by nationalgeographic.pt.

Global survival rates for cancer have shifted significantly over recent decades, rising from 17% in the mid-1990s to 35% by 2021, according to figures from the American Cancer Society reported by nationalgeographic.pt.

“Finally, we are curing metastases,” Joan Massagué, one of the world’s leading cancer authorities, told nationalgeographic.pt.

Massagué and his team demonstrated in an article published on January 13, 2020, in Nature Cancer that certain tumor cells acquire regenerative stem-cell properties that allow them to enter the bloodstream and spread throughout the body, according to Nationalgeographic.

His lab is now testing an existing drug designed to disrupt the genetic program these dormant cells use to remain hidden.

Targeted Treatments for Specific Cancers

At the Institute for Research in Biomedicine (IRB) in Barcelona, molecular biologist Eduard Batlle holds a vial of petosemtamab, a drug developed in his laboratory that has shown promising results for head and neck tumors.

“We are living through a unique moment,” Batlle told nationalgeographic.pt, pointing to long-term remissions for specific subtypes of lung cancer.

Melanoma, which accounts for 1% to 2% of skin cancers, has also seen survival rates jump from below 10% before 2010 to more than 50% today due to immunotherapy advances. HER2-positive breast cancer, representing 15% to 25% of breast tumors, carries a high risk of metastasis if untreated, though targeted therapies have improved long-term management.

Cancer Survival and Treatment Milestones
Cancer Type / Metric Previous Benchmark Recent Progress
Overall US Survival Rate 17% (mid-1990s) 35% (2021)
HER2-Positive Breast Cancer Share 15% to 25% of breast tumors High metastasis risk if untreated

Preventive Vaccine Development

Mary ‘Nora’ L. Disis, director of the Cancer Vaccine Institute at the University of Washington and a researcher at the Fred Hutch Cancer Center, has spent three decades working on immunotherapies and vaccines.

“If you had called me ten years ago, I could only have told you about therapeutic vaccines,” Disis told nationalgeographic.pt.

Researchers are now testing prophylactic vaccines for people with high genetic risk of developing tumors, such as the vaccine designed by Disis, called Stem-Va.

“The goal is to develop a treatment of a few weeks that allows the body to be cleaned of this malignant seed,” Massagué told nationalgeographic.pt.

Born in Barcelona in 1953, Massagué earned his doctorate in biochemistry at the University of Barcelona in 1978 and joined Memorial Sloan Kettering in 1989. He was an investigator at the Howard Hughes Medical Institute from 1990 to 2013 and has served as a scientific advisor at the Institute for Research in Biomedicine in Barcelona since 2005.

In 2013, he was named director of the Sloan Kettering Institute. His lab identified the TGF-β receptors and signaling pathway, and in 2016 defined the basis for metastatic latency in breast and lung cancers after nearly 20 years of research.

About the author: Health Desk

Health Desk at Archynewsy.